Skip to main content
SpringerLink
Log in
Book cover

Opiatabhängigkeit pp 125–138Cite as

Antiretrovirale Therapie

  • Chapter

  • 1693 Accesses

Auszug

Die Verfügbarkeit und Anwendung von wirksamen antiretroviralen Kombinationstherapien sind fast schon zur Selbstverständlichkeit geworden. Mittlerweile wurden über 20 antiretrovirale Substanzen in vier Medikamentenklassen zugelassen; eine fast unübersehbare Vielzahl von Kombinationen ist denkbar. Dies darf nicht darüber hinweg täuschen, dass nur eine kleine Zahl dieser Kombinationen sinnvoll ist.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Mellors JW, Munoz A, Giorgi JV et al (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946–54

    PubMed  CAS  Google Scholar 

  2. Cameron DW, Heath-Chiozzi M, Danner S et al (1998) Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351: 543–9

    Article  PubMed  CAS  Google Scholar 

  3. Hammer SM, Squires KE, Hughes MD et al (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 337: 725–33

    Article  PubMed  CAS  Google Scholar 

  4. Palella FJ Jr, Delaney KM, Moorman AC et al (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853–60

    Article  PubMed  Google Scholar 

  5. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, d’Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119–29

    Article  PubMed  Google Scholar 

  6. Raboud JM, Montaner JS, Conway B et al (1998) Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12: 1619–24

    Article  PubMed  CAS  Google Scholar 

  7. Kempf DJ, Rode RA, Xu Y et al (1998) The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 12: F9–F14

    Article  PubMed  CAS  Google Scholar 

  8. Clavel F, Hance AJ (2004) HIV drug resistance. N Engl J Med 350: 1023–35

    Article  PubMed  CAS  Google Scholar 

  9. Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JS (2003) Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10 (9) cells/L. Ann Intern Med 139: 810–6

    PubMed  Google Scholar 

  10. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 37: 1112–8

    Article  PubMed  Google Scholar 

  11. d’Arminio Monforte A, Testa L, Adorni F et al (1998) Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 12: 1631–7

    Article  PubMed  CAS  Google Scholar 

  12. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, Dabis F, Lundgren J, d’Arminio Monforte A, de Wolf F, Hogg R, Reiss P, Justice A, Leport C, Staszewski S, Gill J, Fatkenheuer G, Egger ME (2003) Antiretroviral Therapy Cohort Collaboration Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 362: 679–86

    Article  PubMed  CAS  Google Scholar 

  13. Lindbäck S, Vizzard J, Cooper DA, Gaines H (1999) Long-term prognosis following Zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. JID 179: 1549–52

    Article  PubMed  Google Scholar 

  14. Kaufmann D, Lichterfeld M, Altfeld M, Allen T, Johnston M et al (2004) Limited durability of immune control following treated acute HIV infection. 11th CROI, Abstr. 24, San Francisco

    Google Scholar 

  15. Hoen B, Fournier I, Charreau I, Lacabaratz C, Burgard M et al (2004) Structured Treatment Interruptions in primary HIV infection: final results of the multicenter prospective PRIMSTOP pilot trial. 11th CROI, Abstr. 395, San Francisco

    Google Scholar 

  16. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM (2004) Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS 18: 709–18

    Article  PubMed  Google Scholar 

  17. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S, Sun EJ (2004) Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Infect Dis 189: 51–60

    Article  CAS  Google Scholar 

  18. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fatkenheuer G, Oette M, Carls H, Fenske S, Nadler M, Knechten H (2000) Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group. AIDS 14: 1181–5

    Article  PubMed  CAS  Google Scholar 

  19. Dragsted UB, Gerstoft J, Pedersen C, Peters B, Duran A, Obel N, Castagna A, Cahn P, Clumeck N, Bruun JN, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, Lundgren JD, MaxCmin1 Trial Group (2003) Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 188: 635–42

    Article  PubMed  CAS  Google Scholar 

  20. Youle M, Gerstoft J, Fox Z, Losso M, Jayaweera DT, Rieger A, Bruun JN, Castagna A, Walmsley S, Hill A, Dragsted UB and Lundgren JD for the MaxCmin2 trial group (2003) The final week 48 analysis of a phase IV, randomized, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir/ritonavir (400/100 mg bid) versus saquinavir/ritonavir (1000/100 mg bid): The MaxCmin2 trial. 9th European AIDS Conference, Warsaw 25–29 October 2003, Abstr. F11/3

    Google Scholar 

  21. Cooper D, Yeni P (2005) Virological and immunological outcome at 3 years following initiation of ART with regimens containing a NNRTI or PI or both: the INITIO trial. 12th CROI, 22–25 Feb 2005, LB 165, Boston.

    Google Scholar 

  22. Staszewski S, Morales-Ramirez J, Tashima KT et al (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341: 1865–1873

    Article  PubMed  CAS  Google Scholar 

  23. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C et al (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 349: 2293–303

    Article  PubMed  CAS  Google Scholar 

  24. Van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A et al (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 17: 987–999

    Article  PubMed  Google Scholar 

  25. Taylor S, Allen S, Fidler S, White D, Gibbons S et al (2004) Stop Study After discontinuation of Efavirenz, plasma concentrations may persist for 2 weeks or longer. 11th CROI, Abstr. 131, San Francisco

    Google Scholar 

  26. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team (2001) Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285: 1155–63

    Article  PubMed  CAS  Google Scholar 

  27. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackmann BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR et al (2004) Triple-nucleoside regimens versus Efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350: 1850–61

    Article  PubMed  CAS  Google Scholar 

  28. Gerstoft J, Kirk O, Obel N, Pedersen C, Mathiesen L, Nielsen H, Katzenstein TL, Lundgren JD (2003) Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. AIDS 17: 2045–52

    Article  PubMed  CAS  Google Scholar 

  29. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41(3): 654–60

    PubMed  CAS  Google Scholar 

  30. Squires KE, Thiry A, Giordano M, for the AI424-034 International Study Team (2002) Atazanavir QD and efavirenz QD with fixeddose ZDV+3TC: Comparison of antiviral efficacy and safety through wk 24 (AI424-034). 42nd ICAAC, Abstract H-1076, San Diego

    Google Scholar 

  31. Stephan C, v. Hentig N, Kourbeti I, Dauer B, Mösch M, Lutz T, Klauke S, Harder S, Kurowski M, Staszewski S (2004) Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18: 503–08

    Article  PubMed  CAS  Google Scholar 

  32. d’Aquila RT, Johnson VA, Welles SL et al (1995) Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 122: 401–408

    PubMed  CAS  Google Scholar 

  33. De Gruttola V, Dix L, d’Aquila R et al (2000) The relationship between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 5: 43–50

    Google Scholar 

  34. Durant J, Clevenbergh F, Halfon F et al (1999) Drug-resistance genotyping in HIV-I therapy: the VIRADAPT randomized controlled trial. Lancet 353: 2195–2199

    Article  PubMed  CAS  Google Scholar 

  35. Baxter JD, Mayers DL, Wentworth DN et al (2000) A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14: F83–93

    Article  PubMed  CAS  Google Scholar 

  36. Cingolani A, Antinori A, Rizzo MG et al (2002) Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 16: 369–379

    Article  PubMed  CAS  Google Scholar 

  37. Tural C, Ruiz L, Holtzer C et al (2002) Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16: 209–218

    Article  PubMed  Google Scholar 

  38. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM, VIRA3001 Study Team (2002) A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16: 579–88

    Article  PubMed  CAS  Google Scholar 

  39. Meynard JL, Vray M, Morand-Joubert L et al (2000) Impact of treatment guided by phenotypic of genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy, 5[suppl] 3: 67–68

    Google Scholar 

  40. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C et al (2004) Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis 38: 723–30

    Article  PubMed  Google Scholar 

  41. The EuroGuidelines Group for HIV Resistance (2001) Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS 15: 309–320

    Article  Google Scholar 

  42. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, d’Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 37: 113–28

    Article  PubMed  Google Scholar 

  43. Wensing AMJ, van de Vijer DAMC, Asjo B, Balotta C, Camacho R, de Luca A, de Mendoza C et al (2003) Analysis from more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10% of the patients carry primary drug resistance: the CATCH-Study. 2nd IAS Conference, Abstr. LB01, Paris

    Google Scholar 

  44. Duwe S, Brunn M, Altmann D et al (2001) Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 26: 266–273

    Article  PubMed  CAS  Google Scholar 

  45. Little SJ, Holte S, Routy J-P, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW et al (2002) Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347: 385–94

    Article  PubMed  CAS  Google Scholar 

  46. Violin M, Cozzi-Lepri A, Velleca R, Vincenti A, Délia S, Chiodo F, Ghinelli F, Bertoli A, d’Arminio Monforte A, Perno CF, Moroni M, Balotta C (2004) Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy. AIDS 18: 227–35

    Article  PubMed  CAS  Google Scholar 

  47. Cane P, Dean G, Fisher M, Pao D, Drake S, Pillay D et al (2004) Persistence of primary genotypic resistance following HIV-1 seroconversion for as long as 3 years post-infection. 11th CROI, Abstr. 684, San Francisco

    Google Scholar 

  48. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV (1999) Indinavir concentrations and antiviral effect. Pharmacotherapy 19: 708–712

    Article  PubMed  CAS  Google Scholar 

  49. Alexander CS, Asselin JJ, Ting LS, Montaner JS, Hogg RS, Yip B, O’Shaughnessy MV, Harrigan PR (2003) Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease. J Infect Dis 188: 541–8

    Article  PubMed  CAS  Google Scholar 

  50. Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM (2003) Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63: 741–53

    Article  PubMed  CAS  Google Scholar 

  51. Mallon PW, Ray J, Cooper DA (2003) Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. J Clin Virol 26: 223–7

    Article  PubMed  CAS  Google Scholar 

  52. Rendon AL, Nunez M, Gonzalez-Requena D, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V (2004) The Benefit of Treatment Interventions Driven by Therapeutic Drug Monitoring. 11th CROI, Abstr. 567, San Francisco

    Google Scholar 

  53. Becher F, Landman R, Mboup S, Toure Kane CN, Canestri A, Liegeois F, Vray M, Prevot MH, Leleu G, Benech H (2004) Monitoring of didanosine and stavudine intracellular triphosporylated anabolite concentration in HIV-infected patients. AIDS 18: 181–87

    Article  PubMed  CAS  Google Scholar 

  54. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S et al (2003) Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial AIDS 17: F33–F37

    Google Scholar 

  55. Fagard C, Oxenius A, Gunthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study (2003) A prospective trial of structured treatment interruptions in human immunodeficiency virus infection. Arch Intern Med 163: 1220–6

    Article  PubMed  Google Scholar 

  56. Dybul M, Nies-Kraske E, Daucher M, Hertogs K, Hallahan CW, Csako G, Yoder C, Ehler L, Sklar PA, Belson M, Hidalgo B, Metcalf JA, Davey RT, Rock Kress DM, Powers A, Fauci AS (2003) Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 188: 388–96

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2. Interne Lungenabteilung, Pulmologisches Zentrum, Sozialmedizinisches Zentrum Baumgartner Höhe, Otto Wagner Spital mit Pflegezentrum, Baumgartner Höhe 1, A-1140, Wien

    OA Dr. med. Brigitte Schmied

Authors
  1. OA Dr. med. Brigitte Schmied
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie, Karl-Franzens-Universität Graz, Graz

    Eckhard Beubler

  2. Verein Wiener Sozialprojekte, Ambulatorium „Ganslwirt”, Wien

    Hans Haltmayer

  3. Ludwig-Boltzmann-Institut für Suchtforschung am Anton-Proksch-Institut, Wien

    Alfred Springer

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag/Wien

About this chapter

Cite this chapter

Schmied, B. (2007). Antiretrovirale Therapie. In: Beubler, E., Haltmayer, H., Springer, A. (eds) Opiatabhängigkeit. Springer, Vienna. https://doi.org/10.1007/978-3-211-69389-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-211-69389-6_13

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-29116-0

  • Online ISBN: 978-3-211-69389-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation